8-K current report · filed Oct 29, 2026

Bristol Myers Squibb (BMY) 8-K Current Report: October 29, 2026

Item 2.02Item 7.01Item EX-99.1Item EX-99.2BMY overview

Short answer

Bristol Myers Squibb (BMY) filed an 8-K current report with the SEC on October 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Bristol-Myers Squibb reported third-quarter 2026 financial results.

Bristol Myers Squibb 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Bristol-Myers Squibb reported third-quarter 2026 financial results
  • Earnings Press Release furnished as Exhibit 99.1, containing the detailed financial results and management commentary

Item 7.01 · Regulation FD Disclosure

  • Bristol Myers posted a presentation covering financial and operating initiatives for its third-quarter 2026 results webcast
  • Materials support investor review of management’s Q3 2026 outlook, performance commentary and strategic priorities
  • Presentation includes non-GAAP measures, with GAAP reconciliations and explanations in the earnings press release

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $13.1B, up 7%, led by Growth Portfolio revenue of $7.7B, up 12%
  • GAAP EPS $1.05 and non-GAAP EPS $1.35, each including a $(0.58) Acquired IPRD and licensing impact
  • 2026 revenue guidance raised to $49.75B-$50.25B, signaling continued portfolio momentum
  • 2026 non-GAAP EPS lowered to $6.35-$6.55, including a $(0.60) Acquired IPRD and licensing impact
  • Gross margin fell to 68.3% from 71.9%, reflecting product mix and a one-time contract termination charge

Item EX-99.2 · Exhibit EX-99.2

  • Q3 revenue $13.1B, up 7% year over year, with Growth Portfolio revenue $7.7B, up 12%
  • Growth led by Eliquis $4.69B, up 25%, plus Camzyos $420M, up 42%, and Breyanzi $526M, up 46%
  • GAAP diluted EPS $1.05 versus $1.08, pressured by acquired IPR&D charges of $1.6B
  • October guidance raised revenue to $49.75B-$50.25B, but diluted EPS reduced to $6.35-$6.55 from $6.75-$7.00
  • Cash ~$13.0B, debt ~$42.9B, and ~$5B remaining share-repurchase authorization support continued capital returns and business development

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Bristol Myers Squibb 8-K filings

Get the next BMY 8-K as it lands

Follow BMY for push alerts, or ask the research agent what this filing means.